The facility is to be built, owned and operated by Moderna, but the exact location has not been determined. Moderna is discussing plans to build more plants in countries in Europe and Asia as well, but didn’t specify which ones, the Journal reported.
The Canadian plant will fulfill Canadian orders for both COVID-19 booster shots and other vaccines the company is developing. It will be able to manufacture any vaccine approved in Canada, Moderna CEO Stéphane Bancel told the Journal.
He added that it will be similar to the drugmaker’s main manufacturing facility in Norwood, Mass., and likely employ a couple hundred people.
Moderna predicts construction will be completed by the end of 2024.
Canada has agreed to purchase a set number of vaccines from the plant, but the government did not disclose how many.
Read the full article here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
